KPV
Research-use contextResearch-use peptide · also: lysine-proline-valine, alpha-msh 11-13
A short peptide fragment of α-MSH studied for anti-inflammatory activity, largely preclinically.
People commonly track it for
Most often logged in a gut / inflammation context (user intent, not a proven effect).
Evidence summary
Largely preclinical. Human clinical evidence is limited.
Regulation & source status
Not FDA-approved. Among the peptides under FDA compounding review as of July 2026 — under review is not approval.
Route considerations
Commonly discussed as an injectable in community settings. We don't provide route, preparation, or technique guidance — that's a clinician/pharmacist conversation.
Storage considerations
Often sold as a powder for reconstitution; unregulated products have no verified storage or stability data. Storage specifics belong to a pharmacist, not this profile.
Interaction & context review
Because human data is limited, interactions aren't well characterized. If you track it alongside other items or medications, review the full list with a clinician or pharmacist.
Track this item
You can log this as a custom peptide / medication-context item — record your own source status, route, storage note, and a schedule, and include it in an export for your clinician. StackWise doesn't add a dose.
Track this itemPeptide safety & source review
Sources
- FDA — PCAC meeting, July 23–24, 2026 (503A bulks review)
- FDA — Understanding the Risks of Compounded Drugs
Source reviewed: 2026-07-23.